A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas

Inclusion Criteria: * Histologically confirmed invasive adenocarcinoma of pancreas. * Stage 4 disease according to The American Joint Committee on Cancer (AJCC the 8th Edition) 2017. * Measurable metastases according to RECIST 1.1. * Patients underwent surgical resection and postoperative evaluation revealed distant metastasis. * Patients with age ranging from 18 to 69. * WHO performance status 0-1. * An adequate bone marrow reserve and adequate liver and renal function as follow: Neutrophils ≥ 1500 cell/dl, Platelets ≥ 100,000 cell/dl, Hemoglobin ≥ 9.0 g/dl, Total bilirubin \< 1.5 × upper normal level (UNL), SGOT and SGPT \< 3 × UNL, Creatinine \< 1.5 × UNL or estimated GFR \> 30 ml/min. * Adjuvant and neoadjuvant chemotherapies will be permitted if administered more than 6 months before inclusion. * Patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting chemotherapy. * All patients must have signed and dated informed consent form. Exclusion Criteria: * Endocrine or acinar pancreatic carcinoma. * Patients who progressed during FOLFRINOX regimen. * Pregnancy or breast feeding. * Patients with complicated systemic diseases such as diabetes, HTN or decompensated liver disease. * Patients with any serious uncontrolled medical conditions that might compromise study participation: Central nervous system disorders, gastrointestinal tract disorders that interfere with oral medication. * Patients with history of previous other carcinoma except basal cell carcinoma of the skin, insitu cervical carcinoma or non-metastatic prostate cancer. * More than grade 1 peripheral neuropathy. * Brain metastasis.